Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial
The BMJ・4 minutes read
Brooke Jackson was terminated in September 2020 after whistleblowing on irregularities in Pfizer's Covid-19 vaccine trial, citing mislabeled specimens and mishandling of vaccines by Ventavia, the trial company, which exhibited unorganized and sloppy practices. The mishandling included used needles in biohazard bags and unblinded participants against regulations, prompting Brooke to report to the FDA and subsequently getting fired.
Insights
- Brooke Jackson was terminated for whistleblowing on irregularities in Pfizer's Covid-19 vaccine trial, highlighting mislabeling, unblinding of patient randomization, and mishandling of vaccines.
- Ventavia, the trial handling company, exhibited disorganization and negligence, with instances of unblinding participants, improper disposal of needles, and delayed reporting of adverse events, prompting Brooke's report to the FDA and subsequent termination.
Get key ideas from YouTube videos. It’s free
Recent questions
What happened to Brooke Jackson in September 2020?
She was fired for whistleblowing on Pfizer's trial irregularities.
What were the irregularities in Pfizer's trial?
Mislabeling, unblinded randomization, and mishandling of vaccines.
Who was responsible for handling Pfizer's trial?
Ventavia was the company handling the trial.
What actions did Brooke Jackson take after discovering irregularities?
She reported the issues to the FDA.
What were the consequences of Brooke Jackson's whistleblowing?
She was fired from her position.
Related videos
Summary
00:00
"Pfizer Whistleblower Exposes Trial Irregularities"
- Brooke Jackson was fired in September 2020 for whistleblowing on irregularities in Pfizer's phase three pivotal trial for their Covid-19 vaccine, including mislabeled specimens, unblinded patient randomization, and mishandling of vaccines.
- Ventavia, the company handling the trial, was found to be unorganized and sloppy, with used needles in biohazard bags, unblinded participants based on CEO directives, and failed to report adverse events promptly, leading Brooke to report them to the FDA on September 25th, resulting in her immediate termination.
